See also: Generic Paxil CR
Paxil is a brand name of paroxetine, approved by the FDA in the following formulation(s):
PAXIL (paroxetine hydrochloride - suspension; oral)
Manufacturer: GLAXOSMITHKLINE
Approval date: June 25, 1997
Strength(s): EQ 10MG BASE/5ML [RLD][AB]
PAXIL (paroxetine hydrochloride - tablet; oral)
Manufacturer: GLAXOSMITHKLINE
Approval date: December 29, 1992
Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 30MG BASE [AB], EQ 40MG BASE [RLD][AB]
Has a generic version of Paxil been approved?
A generic version of Paxil has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Paxil and have been approved by the FDA:
paroxetine hydrochloride suspension; oral
Manufacturer: APOTEX INC
Approval date: December 5, 2006
Strength(s): EQ 10MG BASE/5ML [AB]
paroxetine hydrochloride tablet; oral
Manufacturer: ALPHAPHARM
Approval date: March 8, 2004
Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 30MG BASE [AB], EQ 40MG BASE [AB]
Manufacturer: APOTEX
Approval date: July 30, 2003
Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 30MG BASE [AB], EQ 40MG BASE [AB]
Manufacturer: AUROBINDO PHARMA
Approval date: July 25, 2007
Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 30MG BASE [AB], EQ 40MG BASE [AB]
Manufacturer: CARACO
Approval date: June 29, 2007
Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 30MG BASE [AB], EQ 40MG BASE [AB]
Manufacturer: MYLAN
Approval date: March 13, 2008
Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 30MG BASE [AB], EQ 40MG BASE [AB]
Manufacturer: TEVA
Approval date: August 15, 2005
Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 30MG BASE [AB], EQ 40MG BASE [AB]
Manufacturer: ZYDUS PHARMS USA
Approval date: March 7, 2007
Strength(s): EQ 10MG BASE [AB], EQ 20MG BASE [AB], EQ 30MG BASE [AB], EQ 40MG BASE [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Paxil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Oral liquid compositions containing paroxetine resinate
Patent 5,811,436
Issued: September 22, 1998
Inventor(s): Leonard; Graham Stanley & Cooper; David
Assignee(s): SmithKline Beecham plc
An oral liquid pharmaceutical composition comprising a paroxetine-Amberlite IRP88 complex.
Patent expiration dates:
- September 22, 2015
- March 22, 2016
✓
Pediatric exclusivity
Form of paroxetine hydrochloride anhydrate
Patent 5,872,132
Issued: February 16, 1999
Inventor(s): Ward; Neal & Jacewicz; Victor Witold
Assignee(s): SmithKline Beecham Corporation
"Paroxetine hydrochloride (I) anhydrate ##STR1## free of bound propan-2-ol, and various forms thereof, are useful in the treatment of depression and other disorders for which administration of selective serotonin reuptake inhibitors are indicated."
Patent expiration dates:
- May 19, 2015
- November 19, 2015
✓
Pediatric exclusivity
Form of paroxetine hydrochloride anhydrate
Patent 5,900,423
Issued: May 4, 1999
Inventor(s): Ward; Neal & Jacewicz; Victor Witold
Assignee(s): SmithKline Beecham Corporation
"Paroxetine hydrochloride (I) anhydrate ##STR1## free of bound propan-2-ol, and various forms thereof, are useful in the treatment of depression and other disorders for which administration of selective serotonin reuptake inhibitors are indicated."
Patent expiration dates:
- May 19, 2015
- November 19, 2015
✓
Pediatric exclusivity
Component arrangement for outboard motor
Patent 6,062,927
Issued: May 16, 2000
Inventor(s): Hiraoka; Noriyoshi & Takahashi; Masanori
Assignee(s): Sanshin Kogyo Kabushiki Kaisha
This invention is an outboard motor for use in propelling a watercraft. The motor has a cowling in which is positioned an internal combustion engine. The internal combustion engine comprises a V shaped cylinder block cooperating with first and second cylinder heads to define first and second cylinder banks. The cylinder banks form a valley therebetween. Each of the cylinder banks include at least one combustion chamber. A crankcase is located at an end of the block opposite the heads forming a crankcase chamber. The engine also includes an exhaust system for routing the products of combustion from at least one combustion chamber and an intake system for providing air to the at least one combustion chamber. The intake system includes a single surge tank positioned between the cowling and the crankcase of the engine. At least one first intake pipe extends from the surge tank in a first direction along the cylinder block to the first cylinder head and at least one second intake pipe extends along the cylinder block to the second cylinder head.
Patent expiration dates:
Paroxetine derivatives
Patent 6,063,927
Issued: May 16, 2000
Inventor(s): Craig; Andrew Simon & Jones; Alan David & O'Keeffe; Deirdre & Ward; Neal
Assignee(s): SmithKline Beecham plc
Piperidine compounds, processes for preparing them, pharmaceutical compositions comprising them and their use in therapy are disclosed.
Patent expiration dates:
- April 23, 2019
- October 23, 2019
✓
Pediatric exclusivity
Paroxetine hydrochloride form A
Patent 6,080,759
Issued: June 27, 2000
Inventor(s): Ward; Neal & Jacewicz; Victor Witold
Assignee(s): SmithKline Beecham Corporation
"Paroxetine hydrochloride (I) anhydrate free of bound propan-2-ol, and various forms thereof, are useful in the treatment of depression and other disorders for which administration of selective serotonin reuptake inhibitors are indicated."
Patent expiration dates:
- May 19, 2015
- November 19, 2015
✓
Pediatric exclusivity
Paroxetine tablets and process to prepare them
Patent 6,113,944
Issued: September 5, 2000
Inventor(s): Pathak; Ram Dutta & Doughty; David George
Assignee(s): SmithKline Beecham p.l.c.
Invented is a novel pharmaceutical composition containing Paroxetine.
Patent expiration dates:
- December 14, 2014
- June 14, 2015
✓
Pediatric exclusivity
Paroxetine in the treatment of depression associated with withdrawal from heroin abuse and post-traumatic stress disorder
Patent 6,121,291
Issued: September 19, 2000
Inventor(s): Gleason; Maurice
Assignee(s): SmithKline Beecham plc
This invention relates to the use of paroxetine or a pharmaceutically acceptable salt thereof for the treatment of post-traumatic stress disorder and depression associated with withdrawal from heroin abuse.
Patent expiration dates:
Paroxetine hydrochloride form A or C
Patent 6,133,289
Issued: October 17, 2000
Inventor(s): Ward; Neal & Jacewicz; Victor Witold
Assignee(s): SmithKline Beecham Corporation
Invented are methods of treatment using novel forms of paroxetine hydrochloride anhydrate.
Patent expiration dates:
- May 19, 2015
✓
Patent use: DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
- November 19, 2015
✓
Patent use: DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER
✓
Pediatric exclusivity
Process for making paroxetine
Patent 6,172,233
Issued: January 9, 2001
Inventor(s): Ward; Neal
Assignee(s): SmithKline Beecham plc
Compounds of structure (2) are prepared by reaction of an arecoline analogue of structure(4) with an organometallic compound containing an X-substituted phenyl group, such as a compound of structure (3). ##STR1## Suitably the compound of structure (3) is a Grignard reagent, where M is magnesium and Y is a halogen atom, or M may be a Group II metal and Y is a halogen atom or a second X-substituted phenyl group. When structure (3) is a Grignard reagent, the reaction is carried out either in a suitable non-ether solvent, typically a hydrocarbon or a non-reactive chlorinated hydrocarbon, or in a mixture of such a solvent with diethyl ether. Compounds of structure (2) are important intermediates in the preparation of inter alia paroxetine.
Patent expiration dates:
- January 15, 2018
- July 15, 2018
✓
Pediatric exclusivity
See also...
- Paxil Consumer Information (Drugs.com)
- Paxil Consumer Information (Wolters Kluwer)
- Paxil Suspension Consumer Information (Wolters Kluwer)
- Paxil Consumer Information (Cerner Multum)
- Paxil Advanced Consumer Information (Micromedex)
- Paxil AHFS DI Monographs (ASHP)
- Paroxetine Consumer Information (Drugs.com)
- Paroxetine Consumer Information (Wolters Kluwer)
- Paroxetine Controlled-Release Tablets Consumer Information (Wolters Kluwer)
- Paroxetine Mesylate Consumer Information (Wolters Kluwer)
- Paroxetine Suspension Consumer Information (Wolters Kluwer)
- Paroxetine Consumer Information (Cerner Multum)
- Paroxetine Advanced Consumer Information (Micromedex)
- Paroxetine Hydrochloride AHFS DI Monographs (ASHP)
